Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways

References

• Dutta S, Mahalanobish S, Saha S, et al. Natural products: an upcoming therapeutic approach to cancer. Food Chem Toxicol 2019;128:240–55.
   PubMed Web of Science ®Google Scholar
• Fu YW, Luo JY, Qin JA, Yang MH. Screening techniques for the identification of bioactive compounds in natural products. J Pharm Biomed Anal 2019;168:189–200.
   PubMed Web of Science ®Google Scholar
• Keri RS, Budagumpi S, Pai RK, et al. Chromones as a privileged scaffold in drug discovery: a review. Eur J Med Chem 2014;78:340–74.
   PubMed Web of Science ®Google Scholar
• Rokaya MB, Münzbergová Z, Timsina B, et al. Don: a review of its botany, ethnobotany, phytochemistry and pharmacology. J Ethnopharmacol 2012;141:761–74.
   PubMed Web of Science ®Google Scholar
• Duan YD, Jiang YY, Guo FX, et al. The antitumor activity of naturally occurring chromones: a review. Fitoterapia 2019;135:114–29.
   PubMed Web of Science ®Google Scholar
• Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275:661–5.
   PubMed Web of Science ®Google Scholar
• Franaszek EC, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999;96:8745–50.
   PubMed Web of Science ®Google Scholar
• Medina EA, Morris IR, Berton MT. Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain. J Immunol 2010;185:7562–72.
   PubMed Web of Science ®Google Scholar
• Guo YQ, Yin T, Wang XM, et al. Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: a review. J Ethnopharmacol 2017;209:264–82.
   PubMed Web of Science ®Google Scholar
• Ruhs BN, Julia KCH, William PH, Tor SP. Developing environmentally benign and effective organic wood preservatives by understanding the biocidal and non-biocidal properties of extractives in naturally durable heartwood. Holzforschung 2008;62:264–9.
   Web of Science ®Google Scholar
• Amira MG, Pierre DC, Marguerite T, et al. Anti-cancer and immunostimulatory activity of chromones and other constituents from Cassia petersiana. Z Naturforsch C 2007;62:331–8.
   PubMed Web of Science ®Google Scholar
• Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71.
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Dinakaran M, et al. Discovery of novel antitubercular 2,10-dihydro-4H-chromeno-[3,2-c]pyridin-3-yl derivatives. Eur J Med Chem 2010;45:120–3.
   PubMed Web of Science ®Google Scholar
• Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Safety 2004;27:25–61.
   PubMed Web of Science ®Google Scholar
• Keane WF, Brenner BM. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003;63:1499–507.
   PubMed Web of Science ®Google Scholar
• Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226–35.
   PubMed Web of Science ®Google Scholar
• Yousuf I, Arjmand F, Tabassum SL, et al. Mechanistic insights into a novel chromone-appended Cu(II) anticancer drug entity: in vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF-7 and HepG2 cancer cells. Dalton Trans 2015;44:10330–42.
   PubMed Web of Science ®Google Scholar
• Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241–8.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541–5.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Diaz LAJ, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561–73.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Matos MJ, Garrido J, et al. Chromone: a valid scaffold in medicinal chemistry. Chem Rev 2014;114:4960–92.
   PubMed Web of Science ®Google Scholar
• Klausmeyer P, Zhou Q, Scudiero DA, et al. Cytotoxic and HIF-1α inhibitory compounds from Crossosoma bigelovii. J Nat Prod 2009;72:805–12.
   PubMed Web of Science ®Google Scholar
• Andrioli WJ, Conti R, Araujo MJ, et al. Mycoleptones A-C and polyketides from the endophyte Mycoleptodiscus indicus. J Nat Prod 2014;77:70–8.
   PubMed Web of Science ®Google Scholar
• Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862–8.
   PubMed Web of Science ®Google Scholar
• Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986–97.
   PubMed Web of Science ®Google Scholar
• Itoh N, Semba S, Ito M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127–34.
   PubMed Web of Science ®Google Scholar
• Valdameri G, Genoux-Bastide E, Peres B, et al. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem 2012;55:966–70.
   PubMed Web of Science ®Google Scholar
• Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739–44.
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99–102.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376–87.
   PubMed Web of Science ®Google Scholar
• Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000;9:2903–11.
   PubMed Web of Science ®Google Scholar
• Song QL, Tan SW, Zhuang XT, et al. Nitric oxide releasing D-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin. Mol Pharm 2014;11:4118–29.
   PubMed Web of Science ®Google Scholar
• Bergendi L, Beneš L, Ďuračková Z, et al. Chemistry, physiology and pathology of free radicals. Life Sci 1999;65:1865–74.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521–34.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007;27:317–52.
   PubMed Web of Science ®Google Scholar
• Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev 2012;41:3742–52.
   PubMed Web of Science ®Google Scholar
• Ignarro LJ. Nitric oxide: biology and pathobiology. Cambridge, Massachusetts: Academic Press; 2000.
   Google Scholar
• Sang JR, Chen YC, Tao Y. Nitric oxide inhibits gastric cancer cell growth through the modulation of the Akt pathway. Mol Med Rep 2011;4:1163–7.
   PubMed Web of Science ®Google Scholar
• De Luca A, Moroni N, Serafino A, et al. Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochem J 2011;440:175–83.
   PubMed Web of Science ®Google Scholar
• Chung MF, Liu HY, Lin KJ, et al. A pH-responsive carrier system that generates NO bubbles to trigger drug release and reverse P-glycoprotein-mediated multidrug resistance. Angew Chem Int Ed 2015;54:9890–3.
   PubMed Web of Science ®Google Scholar
• Rapozzi V, Della Pietra E, Zorzet S, et al. Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide 2013;30:26–35.
   PubMed Web of Science ®Google Scholar
• Xiang HJ, Deng Q, An L, et al. Tumor cell specific and lysosome-targeted delivery of nitric oxide for enhanced photodynamic therapy triggered by 808 nm near-infrared light. Chem Commun 2016;52:148–51.
   PubMed Web of Science ®Google Scholar
• Huang L, Gao Z, Han G. Photoswitchable near-infraredemitting borondipyrromethene (BODIPY) nanoparticles. Part Part Syst Char 2017;34:1700223.
   Web of Science ®Google Scholar
• De Ridder M, Verellen D, Verovski V, et al. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008;19:164–9.
   PubMed Web of Science ®Google Scholar
• Fan W, Bu W, Zhang Z, et al. X-ray radiation-controlled NO-release for on-demand depth independent hypoxic radiosensitization. Angew Chem Int Ed 2015;54:14026–30.
   PubMed Web of Science ®Google Scholar
• Liu J, Li C, Qu W, et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 2004;3:709–14.
   PubMed Web of Science ®Google Scholar
• Zhang K, Xu H, Jia Y, et al. Ultrasound-triggered nitric oxide release platform based on energy transformation for targeted inhibition of pancreatic tumor. ACS Nano 2016;10:10816–28.
   PubMed Web of Science ®Google Scholar
• Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci 1999;890:301–11.
   PubMed Web of Science ®Google Scholar
• Feng T, Wan J, Li P, et al. A novel NIR-controlled NO release of sodium nitroprusside-doped Prussian blue nanoparticle for synergistic tumor treatment. Biomaterials 2019;214:119213.
   PubMed Web of Science ®Google Scholar
• Burgaud J-L, Ongini E, Soldato P. Nitric oxide-releasing drugs-a novel class of effective and safe therapeutic agents. Ann NY Acad Sci 2002;962:360–71.
   PubMed Web of Science ®Google Scholar
• Chiueh CC, Hong JS, Leong SK. Nitric oxide: novel actions, deleterious effects, and clinical potential. Ann N Y Acad Sci 2002;402–14.
   Google Scholar
• Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics. Int J Oncol 2008;33:909–27.
   PubMed Web of Science ®Google Scholar
• Serafim RAM, Primi MC, Trossini GHG, Ferreira EI. Nitric oxide: state of the art in drug design. Curr Med Chem 2012;19:386–405.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Blake M, de la Mata-Moya MD, et al. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced nonsmall cell lung cancer. Radiother Oncol 2014;111:311–15.
   PubMed Web of Science ®Google Scholar
• Bonavida B, Baritaki S, Huerta-Yepez S, et al. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 2008;19:152–57.
   PubMed Web of Science ®Google Scholar
• Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. Redox Biol 2015;6:486–94.
   PubMed Web of Science ®Google Scholar
• Lai Y, Shen L, Zhang Z, et al. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents. Bioorg Med Chem Lett 2010;20:6416–20.
   PubMed Web of Science ®Google Scholar
• Aguirre G, Boiani M, Cerecetto H, et al. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies. Pharmazie 2006;61:54–59.
   PubMed Web of Science ®Google Scholar
• Hu X, Jiao RW, Li HN, et al. Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties. Eur J Med Chem 2018;151:376–88.
   PubMed Web of Science ®Google Scholar
• Han T, Tian KT, Pan HQ, et al. Novel hybrids of brefeldin A and nitrogen mustards with improved antiproliferative selectivity: design, synthesis and antitumor biological evaluation. Eur J Med Chem 2018;150:53–63.
   PubMed Web of Science ®Google Scholar
• Ling Y, Ye X, Zhang Z, et al. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. J Med Chem 2011;54:3251–59.
   PubMed Web of Science ®Google Scholar
• André F, Joana R, Tiago S, et al. Coumarin versus chromone monoamine oxidase B inhibitors: quo vadis? J Med Chem 2017;60:7206–12.
   PubMed Web of Science ®Google Scholar
• Novak M, Žegura B, Baebler Š, et al. Influence of selected anti-cancer drugs on the induction of DNA double-strand breaks and changes in gene expression in human hepatoma HepG2 cells. Environ Sci Pollut R 2016;23:14751–61.
   PubMed Web of Science ®Google Scholar
• Hussein EM, Al-Rooqi MM, Abd El-Galil SM, et al. Design, synthesis, and biological evaluation of novel N4-substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors. BMC Chem 2019; 13(1):91.
   PubMed Web of Science ®Google Scholar
• Kumar S, Lim SM, Ramasamy K, et al. Design, synthesis, antimicrobial and cytotoxicity study on human colorectal carcinoma cell line of new 4,4′-(1,4-phenylene) bis(pyrimidin-2-amine) derivatives. Chem Cent J 2018;12(1):73.
   PubMedGoogle Scholar
• Liu X, Chan SY, Chi-Lui Ho P. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemoth Pharm 2008;63:167–74.
   PubMed Web of Science ®Google Scholar
• Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 2008;76:1590–611.
   PubMed Web of Science ®Google Scholar
• Mortimer CG, Wells G, Wells JP, et al. Antitumor benzothiazoles. 26.1 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J Med Chem 2006;49:179–85.
   PubMed Web of Science ®Google Scholar
• Chan KT, Meng FY, Li Q, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010;294:118–24.
   PubMed Web of Science ®Google Scholar
• Shen JK, Du HP, Yang M, et al. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol 2009;88:743–52.
   PubMed Web of Science ®Google Scholar
• Yang L, Wu S, Zhang Q, et al. 24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria-dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett 2007;256:0–278.
   Web of Science ®Google Scholar
• Li JF, Huang RZ, Yao GY, et al. Synthesis and biological evaluation of novel aniline-derived asiatic acid derivatives as potential anticancer agents. Eur J Med Chem 2014;86:175–88.
   PubMed Web of Science ®Google Scholar
• Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008;19:205–16.
   PubMed Web of Science ®Google Scholar
• Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95 and ceramide-induced apoptosis. J Exp Med 1997;186:25–37.
   PubMed Web of Science ®Google Scholar
• Stefano S, Cristiana B, Jurek D, et al. Opposite role of changes in mitochondrial membrane potential in different apoptotic processes. FEBS Lett 2000;469:186–90.
   PubMed Web of Science ®Google Scholar
• Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147–57.
   PubMed Web of Science ®Google Scholar
• Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996;184:1331–41.
   PubMed Web of Science ®Google Scholar
• Jeong SY, Gaume B, Lee YJ, et al. Bcl-x(L) sequesters its C-terminal membrane anchor in soluble, cytosolic homodimers. Embo J 2004;23:2146–55.
   PubMed Web of Science ®Google Scholar
• Renault TT, Floros KV, Chipuk JE. BAK/BAX activation and cytochrome c release assays using isolated mitochondria. Methods 2013;61:146–55.
   PubMed Web of Science ®Google Scholar
• Jo EB, Lee YS, Lee H, et al. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer 2019;19:496.
   PubMed Web of Science ®Google Scholar
• Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37:517–54.
   PubMed Web of Science ®Google Scholar
• Goo HG, Rhim H, Kang S. HtrA2/Omi influences the stability of LON protease 1 and prohibitin, proteins involved in mitochondrial homeostasis. Exp Cell Res 2014;328:456–65.
   PubMed Web of Science ®Google Scholar
• Yamauchi S, Hou YY, Guo AK, et al. p53-mediated activation of the mitochondrial protease HtrA2/Omi prevents cell invasion. J Cell Biol 2014;204:1191–207.
   PubMed Web of Science ®Google Scholar
• Wang CY, Cusack JJC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412–17.
   PubMed Web of Science ®Google Scholar
• Lüpertz R, Chovolou Y, Kampkötter A, et al. Catalase overexpression impairs TNF-alpha induced NF-kappaB activation and sensitizes MCF-7 cells against TNF-alpha. J Cell Biochem 2008;103:1497–511.
   PubMed Web of Science ®Google Scholar
• Lin SY, Li K, Stewart GS, Elledge SJ. Human claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci USA 2004;101:6484–89.
   PubMed Web of Science ®Google Scholar
• Lam MH, Liu Q, Elledge SJ, et al. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004;6:45–59.
   PubMed Web of Science ®Google Scholar
• Azenha D, Lopes MC, Martins TC. Claspin functions in cell homeostasis-A link to cancer?. DNA Repair 2017;59:27–33.
   PubMed Web of Science ®Google Scholar
• Tsimaratou K, Kletsas D, Kastrinakis NG, et al. Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol 2007;211:331–39.
   PubMed Web of Science ®Google Scholar